Phase 2 Study of 99mTc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection
暂无分享,去创建一个
John Babich | Thomas Strack | Steven Joniau | E. Klein | N. Stambler | K. Goffin | S. Joniau | J. Babich | K. Slawin | P. Tenke | Thomas Armor | Eric A Klein | T. Strack | Nancy Stambler | Karolien E Goffin | Vivien Wong | Peter Tenke | Kevin Slawin | T. Armor | Vivien Wong
[1] Toby C. Cornish,et al. 18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer , 2015, The Journal of Nuclear Medicine.
[2] Matthias D Hofer,et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. , 2007, Human pathology.
[3] K. Rahbar,et al. Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study , 2015, EJNMMI Research.
[4] M. Haider,et al. The expanding role of MRI in prostate cancer. , 2013, AJR. American journal of roentgenology.
[5] S. Vallabhajosula,et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] S. Vallabhajosula,et al. 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer , 2014, The Journal of Nuclear Medicine.
[7] William C. Eckelman,et al. First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer , 2013, The Journal of Nuclear Medicine.
[8] Esther Mena,et al. Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer , 2015, Molecular Imaging and Biology.
[9] H. Heinzer,et al. Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. , 2016, European urology.
[10] T. Holland-Letz,et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[11] D. Bostwick,et al. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen , 1998, Cancer.
[12] M. Bock,et al. MRI versus 68Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[13] P. Wolf,et al. Targeted therapies for prostate cancer against the prostate specific membrane antigen. , 2009, Current drug targets.
[14] G. Reischl,et al. PET Imaging of Prostate Cancer Xenografts with a Highly Specific Antibody against the Prostate-Specific Membrane Antigen , 2009, Journal of Nuclear Medicine.
[15] W. Heston,et al. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer , 2004, Journal of cellular biochemistry.
[16] W. Eckelman,et al. 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer , 2013, The Journal of Nuclear Medicine.
[17] B. Hadaschik,et al. Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[18] Guilherme Godoy,et al. Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement. , 2011, European urology.
[19] Hedvig Hricak,et al. Pretreatment evaluation of prostate cancer: role of MR imaging and 1H MR spectroscopy. , 2004, Radiographics : a review publication of the Radiological Society of North America, Inc.
[20] K. Rahbar,et al. Correlation of Intraprostatic Tumor Extent with 68Ga-PSMA Distribution in Patients with Prostate Cancer , 2016, The Journal of Nuclear Medicine.
[21] U. Haberkorn,et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. , 2012, Bioconjugate chemistry.
[22] M. Schwaiger,et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy , 2015, The Journal of Nuclear Medicine.
[23] Clemens Decristoforo,et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[24] T. Holland-Letz,et al. Intra-individual comparison of 68Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[25] M. Schwaiger,et al. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer , 2017, The Journal of Nuclear Medicine.
[26] J. Fütterer,et al. ESUR prostate MR guidelines 2012 , 2012, European Radiology.
[27] S. Landas,et al. Expression of Prostate-Specific Membrane Antigen in Normal and Malignant Human Tissues , 2006, World Journal of Surgery.
[28] U. Haberkorn,et al. [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[29] Namkug Kim,et al. Functional MR imaging of prostate cancer. , 2007, Radiographics : a review publication of the Radiological Society of North America, Inc.
[30] N. Bander,et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. , 2000, Cancer research.
[31] M. Picchio,et al. Initial prostate cancer diagnosis and disease staging—the role of choline-PET–CT , 2015, Nature Reviews Urology.